MacroGenics Inc. (NASDAQ:MGNX) shares were down 1.5% during mid-day trading on Friday . The stock traded as low as $29.46 and last traded at $29.61, with a volume of 67,210 shares traded. The stock had previously closed at $30.05.

Several research analysts have issued reports on MGNX shares. Wedbush reissued an “outperform” rating and set a $52.00 price objective on shares of MacroGenics in a research report on Wednesday, May 18th. Leerink Swann reaffirmed an “outperform” rating and issued a $47.00 target price on shares of MacroGenics in a report on Thursday, May 19th. Morgan Stanley reaffirmed a “hold” rating on shares of MacroGenics in a report on Thursday, May 19th. BTIG Research reaffirmed a “buy” rating and issued a $35.00 target price on shares of MacroGenics in a report on Sunday, May 22nd. Finally, Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of MacroGenics in a report on Tuesday, June 14th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $38.71.

The stock’s market capitalization is $1.03 billion. The company has a 50-day moving average of $30.18 and a 200-day moving average of $23.42.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.12 EPS for the quarter, beating the consensus estimate of ($0.02) by $1.14. The company had revenue of $80.67 million for the quarter, compared to analyst estimates of $27.22 million. During the same quarter last year, the business earned ($0.71) EPS. The company’s revenue for the quarter was up 1100.4% on a year-over-year basis. Equities research analysts expect that MacroGenics Inc. will post ($1.29) EPS for the current fiscal year.

In other MacroGenics news, VP Lynn Cilinski sold 8,922 shares of the stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $27.22, for a total transaction of $242,856.84. Following the transaction, the vice president now owns 10,845 shares in the company, valued at $295,200.90. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CMO Jon Marc Wigginton sold 5,000 shares of the stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $27.22, for a total value of $136,100.00. Following the transaction, the chief marketing officer now owns 5,000 shares in the company, valued at approximately $136,100. The disclosure for this sale can be found here.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.